• DOI:10.1016/S0140-6736(20)32013-4
Corpus ID: 222135901

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

@article{Palfree2020LopinavirritonavirIP,
  title={Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial},
  author={Peter W Marion Jennifer L Louise Natalie Jonathan Adrian Horby Mafham Bell Linsell Staplin Emberson Palfree and P. Horby and M. Mafham and J. Bell and L. Linsell and N. Staplin and J. Emberson and A. Palfreeman and J. Raw and E. Elmahi and B. Prudon and C. Green and S. Carley and D. Chadwick and M. Davies and M. Wise and J. K. Baillie and L. Chappell and S. Faust and T. Jaki and K. Jefferey and W. Lim and A. Montgomery and K. Rowan and E. Juszczak and R. Haynes and M. Landray},
  journal={Lancet (London, England)},
  year={2020},
  volume={396},
  pages={1345 - 1352}
}

• Peter W Marion Jennifer L Louise Natalie Jonathan Adrian Horby Mafham Bell Linsell Staplin Emberson Palfree, P. Horby, +24 authors M. Landray
• Published 2020
• Medicine
• Lancet (London, England)

Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19… Expand